The publication of positive Phase 2 study results in a reputable journal like the New England Journal of Medicine is likely to boost investor confidence in BridgeBio Pharma. The significant increase in annualized height velocity for children with achondroplasia suggests strong potential for infigratinib, which could lead to future revenue growth if the drug progresses successfully through further trials and regulatory approval.